证券日报网讯 1月22日，国际医学在互动平台回答投资者提问时表示，本次非公开发行已经公司第十三 届董事会第九次会议、2025年第二次临时股东会审议通过，募集资金拟用于智慧康养项目、质子治疗中 心二期项目及补充流动资金。根据《上市公司募集资金监管规则》，公司募集资金使用应当专款专用。 任何对既定募投计划的重大调整，都必须严格遵循法定程序。有关本次发行的后续进展，请关注相关公 告。 （文章来源：证券日报） ...

据交易所数据显示， 国际医学8天4板，今日于9时41分封涨停，成交额12.49亿元，换手率9.41%。金融 界App AI线索挖掘：近期 医疗服务板块表现活跃，国际医学被确立为国际医疗旅游试点示范基地，充 分利用自身资源平台对接海外合作伙伴，加强与 一带一路沿线国家在国际医疗旅游服务业务等医疗卫 生领域的交流合作；公司也对包括 脑机接口在内的现代前沿医学技术保持高度关注，本次非公开发行 募集资金拟用于智慧康养项目、质子治疗中心二期项目及补充流动资金，相关业务布局受到市场关注。 风险提示：连板股波动剧烈，注意追高风险，理性投资！（注：以上由AI基于交易所等公开数据生 成，内容不构成投资建议。） ...

Group 1 - The core viewpoint of the article is that the International Medical Proton Therapy Center's Phase I project is progressing as planned and will commence operations upon obtaining the necessary administrative approvals [1] - The company will determine the specific investment progress of the Phase II project based on the actual amount raised from the current private placement [1]

Core Insights - The article highlights the advancements in proton therapy technology by China General Nuclear Power Group (CGN) and its subsidiary, CGN Medical Technology, which has established the first commercial multi-room proton therapy system production base in China [1] - The 230 MeV cyclotron, a key component of the proton therapy system, has been successfully produced, with three units completed in the first year of operation [1] - The company aims to achieve a world-class nuclear medical industry by 2030, leveraging local research and manufacturing capabilities in Mianyang, Sichuan [1] Company Overview - CGN Medical Technology has adopted a strategy of "introduction, digestion, absorption, and re-innovation" to develop its proton therapy systems, following successful practices in China's nuclear power sector [1] - The proton therapy system consists of 227 main devices and approximately 155,000 components, showcasing its complexity and technological sophistication [1] - The company has formed partnerships with over 80 upstream and downstream enterprises in the industry, promoting continuous technological innovation [1] Industry Context - The Sichuan province has implemented supportive policies to foster the development of the nuclear medical industry, aiming to establish itself as a global leader in medical isotope production and nuclear medical equipment manufacturing by 2030 [1] - The region's strong research and manufacturing foundation, exemplified by institutions like the China Engineering Physics Research Institute, contributes to the rapid growth of the nuclear medical sector in Mianyang [1] - The article emphasizes the potential for China to export its advanced imaging and treatment technologies internationally, marking a significant step in the global nuclear medical landscape [1]

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 5.5 yuan, compared to the current price of 4.79 yuan [3][7]. Core Insights - The company reported a revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94%. The net profit attributable to the parent company was a loss of 294 million yuan, with a year-on-year increase in losses of 38.45% [2][7]. - The decline in revenue is attributed to two main factors: adjustments in medical insurance payment policies leading to a decrease in inpatient service volume and the ongoing reform of the DRG payment method, which has reduced the average cost per inpatient [7]. - Despite the short-term pressure on revenue, the company has seen a steady increase in outpatient and emergency services, with a total of 1.9751 million visits, a year-on-year increase of 4.03% [7]. - The company is focusing on strategic growth areas, including high-barrier projects like the proton therapy center, consumer healthcare, and data assetization, which are expected to enhance long-term competitiveness [7]. Financial Summary - For 2025, the company is projected to have total revenue of 4.055 billion yuan, a decrease of 15.8% year-on-year, with a net profit attributable to the parent company expected to be a loss of 343 million yuan [2][8]. - The company’s financial metrics indicate a projected net profit growth rate of 74.5% in 2026 and 214.8% in 2027, suggesting a potential recovery in profitability [8]. - The company’s total assets are estimated to be 10.422 billion yuan in 2025, with a debt-to-equity ratio of 164.2% [8].

Core Viewpoint - The company provided insights into the operational budget of its proton therapy center, highlighting the complexity and high costs associated with such medical facilities [1] Group 1: Operational Budget Components - The operational costs of the proton therapy system include fixed asset depreciation and amortization, equipment maintenance and operational costs, daily operational expenses, and labor costs [1] - The proton therapy project is characterized by high technical barriers, large investment scale, and long return periods [1] Group 2: Break-even Point and Demand - The break-even point for the proton therapy center is influenced by various dynamic factors [1] - The Xi'an International Medical Center's proton therapy center is the first of its kind in Northwest China and will officially commence operations after obtaining the necessary administrative approvals [1]

Carbon Neutrality - The State Council's white paper emphasizes the importance of energy storage in building a new power system, promoting the integration of "new energy + storage" and multi-energy complementarity [1] - By the end of 2024, new energy storage installations are expected to reach 73.76 million kilowatts (168 million kilowatt-hours), which is 20 times that of 2020, accounting for over 40% of global installations [1] Space Computing - Several U.S. space companies are advancing orbital data center plans, utilizing solar energy to address AI energy consumption [2] - SpaceX is expected to increase its share of global orbital launches from 90% to 99% with the frequent launches of Starship [2] - The competition in space computing is intensifying, with China leading in the development of space computing capabilities [3] Ultra High Definition Video - The World Ultra High Definition Video Industry Alliance held a conference in Shenzhen, releasing key technologies and marking a new stage in the industrialization of ultra HD standards in China [4] - The market for ultra HD video is projected to reach 5-6 trillion yuan by 2025, driven by the rapid development of new displays and consumer electronics [4] Proton Therapy - An international standard for medical proton accelerators has been published, highlighting the global collaboration in developing advanced cancer treatment technologies [5] Smart Agriculture - The Ministry of Agriculture and Rural Affairs released guidelines for building a smart agriculture standard system by 2030, aiming to enhance agricultural efficiency and technology [6] E-sports - The KPL annual finals set a Guinness World Record for the highest attendance at an e-sports event, with 62,196 attendees [6] - The e-sports industry is evolving into a significant cultural phenomenon, with increasing integration into the entertainment sector [6] Commercial Space - The successful launch of the Kuaizhou-1A rocket marks a milestone for China's commercial space sector, with significant advancements in reusable rocket technology [7] Macro and Industry News - The State Council issued opinions to accelerate the application of new scenarios in artificial intelligence and promote clean energy in coal and new energy integration [8]

Core Insights - IBA reported strong revenue growth and improved profitability in the first half of 2025, driven by effective backlog conversion [2][4] Financial Performance - Total net sales increased by 40% year-over-year to EUR 304.9 million, with IBA Clinical and IBA Technologies growing by 47% and 30% respectively [3][4] - Gross profit rose to EUR 90.0 million, a 27% increase, while gross margin decreased to 29.5% from 32.6% due to a less favorable equipment profitability mix [3][4] - Operating expenses (OPEX) were controlled at EUR 79.4 million, representing 26% of total net sales, leading to a REBITDA of EUR 16.4 million, up 141% from the previous year [3][4] - The company reported a net loss of EUR 2.6 million, an improvement from a loss of EUR 10.3 million in H1 2024, attributed to non-recurring expenses and foreign exchange fluctuations [4] Order Intake and Backlog - Equipment order intake was EUR 107 million, a decrease of 7% compared to H1 2024, with a notable decline in Proton Therapy orders by 35% [5] - The backlog decreased to EUR 1.3 billion, driven by increased backlog conversion, with expectations for H2 order intake to be stronger [5] Strategic Developments - IBA's new CFO, Catherine Vandenborre, started on July 1, 2025, as part of the company's strategic initiatives [5] - The company reaffirmed its 2025 guidance, targeting a Group REBIT of at least EUR 25 million by year-end, supported by positive performance in Proton Therapy [6] Operational Highlights - PanTera began production of Actinium-225 in Belgium to support clinical trials, with a large-scale facility expected to break ground in Q4 2025 [5][6] - The company is implementing a new Enterprise Resource Planning (ERP) system, anticipated to be completed by early 2026 [7]

Group 1: Company Performance Overview - In the first half of 2025, the company achieved a total outpatient and emergency service volume of 1.3191 million, a year-on-year increase of 5.42% [4] - The company reported operating revenue of CNY 2,034.31 million, a decrease of 15.95% year-on-year, and a net profit attributable to shareholders of CNY -164.96 million, a year-on-year decrease in loss of 4.98% [4] - The operating cash flow net amount was CNY 592.54 million, an increase of 12.75% compared to the same period last year [4] Group 2: Service and Operational Improvements - The company established a senior care center with 100 beds to cater to the needs of elderly patients, including those with Alzheimer's and other disabilities [2] - The company’s hospitals completed 636 clinical application filings for restricted technologies and published 39 SCI papers, enhancing their academic influence [2] - The company improved patient service experience by optimizing the hospitalization settlement and medical insurance reimbursement processes [3] Group 3: Financial Metrics and Cost Management - In Q2 2025, the company achieved operating revenue of CNY 1.037 billion, a quarter-on-quarter increase of 4.02% [4] - The management expense ratio in Q2 was 13.12%, a decrease of 0.95 percentage points from the previous quarter [4] - The company implemented cost control measures, including optimizing personnel costs and enhancing procurement efficiency [6] Group 4: Patient Demographics and Market Reach - The proportion of out-of-town patients at Xi'an Gaoxin Hospital increased to 35%, while at Xi'an International Medical Center Hospital, it rose to 42% from less than 10% [7] - The company is adapting to DRG payment reform, stabilizing inpatient service volume while expanding outpatient services [6] Group 5: Future Outlook and Strategic Initiatives - The company plans to enhance medical quality and service experience while implementing differentiated strategies to build competitive advantages [9] - The proton therapy center, set to open in 2025, will be the first of its kind in Northwest China, significantly improving cancer treatment capabilities in the region [9]

Core Viewpoint - Guangzhou Taihe Hospital Proton Center has been recognized as the third-best proton therapy center in China for the 2024-2025 period, highlighting its exceptional treatment capabilities and quality medical services [2][5]. Industry Overview - The proton and heavy ion therapy sector in China is experiencing rapid growth, with the National Health Commission increasing the permitted number of proton and heavy ion therapy devices from 19 to 60 in its 14th Five-Year Plan, significantly boosting industry development [8]. - As of early 2025, there are 10 proton and heavy ion centers operational in mainland China, allowing more cancer patients to access this advanced precision radiotherapy technology [8]. Company Highlights - The Guangzhou Taihe Hospital Proton Center is the only clinical proton therapy center in South China, supported by the renowned MD Anderson Cancer Center, and adheres to international treatment standards [2][8]. - The center is equipped with the first Varian ProBeam proton therapy system in South China, which features advanced technology such as superconducting cyclotron and 360° rotating gantry [9]. - The expert team at the center consists of professionals with extensive experience from top medical institutions, emphasizing international academic exchange and training [10]. Treatment Efficacy - The proton therapy center has successfully treated patients aged 1 to 90, covering various types of cancers, including pediatric tumors and central nervous system tumors, demonstrating significant treatment outcomes [14]. - Clinical cases show remarkable results, such as a young patient with thymoma experiencing near-complete tumor regression after 30 sessions of proton therapy, and a 10-year-old patient with chemotherapy-resistant cancer showing significant improvement after 33 sessions [14]. Patient Experience - Patients express gratitude for the compassionate care received at the center, highlighting the dedication of the medical team and the personalized treatment plans [15]. - The hospital's director emphasizes the recognition as a top institution reflects the commitment to patient-centered care and the ongoing collaboration with international institutions to advance proton therapy technology [15].